Cutaneous Manifestations of COVID-19: A Comprehensive Review

Sarah Daniel^*
*Correspondence: Sarah Daniel, Department of Dermatology, University of Houston, 4300 Martin Luther King Blvd, Houston, TX 77204, USA, Email:

Keywords

COVID-19 • Cutaneous • Predominant

Introduction

The emergence of the novel coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 has led to a global health crisis, affecting millions of individuals worldwide. While primarily recognized as a respiratory illness, COVID-19 has been associated with a spectrum of extra pulmonary manifestations, including cutaneous involvement. The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has presented an unprecedented global health crisis, challenging healthcare systems worldwide. While respiratory symptoms remain the hallmark of COVID-19, emerging evidence has shed light on the diverse array of cutaneous manifestations associated with the disease. These dermatological findings range from mild rashes to severe manifestations, encompassing a spectrum of clinical presentations that have significant implications for diagnosis, management, and patient care. Understanding these cutaneous manifestations is crucial not only for accurate diagnosis but also for recognizing potential systemic implications of COVID-19 infection [1].

The exploration of COVID-19-related dermatological manifestations represents a rapidly evolving field in dermatology and infectious disease research. The recognition of these manifestations is essential for clinicians across various specialties, as they may serve as early indicators of COVID-19 infection or complications. Additionally, the presence of dermatological symptoms can significantly impact patient management, influencing decisions regarding isolation protocols, diagnostic testing, and therapeutic interventions. Furthermore, the characterization of cutaneous manifestations associated with COVID-19 provides valuable insights into the pathophysiological mechanisms underlying the disease, offering potential avenues for targeted therapeutic interventions and preventive strategies. This comprehensive review aims to synthesize the current literature on cutaneous manifestations of COVID-19, providing a nuanced understanding of their clinical features, pathogenesis, and implications for patient care. By elucidating the dermatological aspects of COVID-19, healthcare professionals can enhance their diagnostic acumen, improve patient outcomes, and contribute to the ongoing efforts to combat the pandemic [2].

Literature Review

COVID-19-related dermatologic manifestations encompass a diverse array of clinical presentations, ranging from nonspecific erythematous rashes to more distinctive patterns such as urticaria, livedo reticularis, and chilblain-like lesions. These cutaneous manifestations may manifest at various stages of the disease, including during the prodromal phase, concurrent with respiratory symptoms, or as late sequelae following resolution of systemic illness. Furthermore, dermatologic findings in COVID-19 patients may exhibit considerable heterogeneity, reflecting the multifactorial nature of viral pathogenesis, immune dysregulation, and host response variability. The pathophysiology underlying COVID-19-associated dermatologic manifestations remains incompletely understood but is thought to involve direct viral cytopathic effects, immune-mediated mechanisms, and systemic inflammatory responses. Additionally, certain dermatologic manifestations, such as acral lesions resembling chilblains, have raised intriguing questions regarding the potential role of microvascular thrombosis and coagulopathy in COVID-19 pathogenesis. Understanding the clinical spectrum, temporal course, and potential implications of cutaneous manifestations in COVID-19 patients is crucial for clinicians to recognize, evaluate, and manage dermatologic findings in the context of systemic disease [3].

Discussion

Cutaneous manifestations of COVID-19 encompass a diverse spectrum of dermatological findings, including maculopapular rashes, urticaria, vesicular eruptions, livedo reticularis, chilblain-like lesions and others. These manifestations may present as early or late symptoms of COVID-19 infection or as a consequence of the immune response to the virus. The pathogenesis of COVID-19-associated skin manifestations remains multifactorial, involving direct viral effects, immune-mediated mechanisms, and systemic inflammatory responses. SARS-CoV-2 may directly infect cutaneous cells expressing Angiotensin-Converting Enzyme 2 receptors, leading to viral replication and local tissue damage. Additionally, dysregulated immune responses triggered by the virus can result in cytokine storms and autoimmune reactions, contributing to the development of dermatological manifestations. Furthermore, COVID-19- associated coagulopathy and microvascular thrombosis may underlie certain cutaneous findings such as livedo reticularis and acro-ischemic lesions. By exploring the diverse pathophysiological mechanisms underlying COVID-19- related dermatological manifestations, clinicians can gain insights into the disease's systemic impact and tailor management strategies accordingly [3-6].

Conclusion

In conclusion, the recognition and characterization of cutaneous manifestations in COVID-19 patients are essential components of comprehensive patient care and public health efforts during the ongoing pandemic. While COVID-19 primarily manifests as a respiratory illness, dermatologic involvement can serve as an important diagnostic clue, particularly in cases with atypical or nonspecific clinical presentations. Moreover, dermatologic findings may provide insights into the underlying pathophysiology of COVID-19 and its systemic implications, highlighting the interconnectedness between viral infection, immune responses, and cutaneous manifestations. Moving forward, continued vigilance and collaboration among clinicians, dermatologists, and researchers are paramount for elucidating the full spectrum of COVID-19-related dermatologic manifestations, refining diagnostic criteria, and optimizing therapeutic strategies. By leveraging collective expertise and evidence-based approaches, the medical community can effectively navigate the complexities of COVID-19-associated dermatologic findings and mitigate the impact of the pandemic on patient outcomes and public health.

In conclusion, the recognition and understanding of cutaneous manifestations associated with COVID-19 are critical for comprehensive patient care and disease management. Dermatological findings may serve as valuable diagnostic clues, especially in cases with atypical or mild respiratory symptoms. Moreover, the presence of cutaneous manifestations may indicate the severity of systemic disease and guide treatment decisions. As our understanding of COVID-19-related dermatological manifestations continues to evolve, further research is warranted to elucidate their pathogenesis, prognostic significance, and implications for patient outcomes. By integrating dermatological assessments into the clinical evaluation of COVID-19 patients, healthcare professionals can enhance diagnostic accuracy, optimize treatment strategies, and improve overall patient care in the midst of this global health crisis.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Freeman, Esther E., Devon E. McMahon, Jules B. Lipoff and Misha Rosenbach, et al. "The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries." J Am Acad Dermatol 83 (2020): 1118-1129.

Google Scholar, Crossref, Indexed at

2. Galván Casas, C., A. C. H. G. Catala, G. Carretero Hernández and P. Rodríguez‐Jiménez, et al. "Classification of the cutaneous manifestations of COVID‐19: A rapid prospective nationwide consensus study in Spain with 375 cases." Br J Dermatol 183 (2020): 71-77.

Google Scholar, Crossref, Indexed at

3. Marzano, Angelo Valerio, Giovanni Genovese, Gabriella Fabbrocini and Paolo Pigatto, et al. "Varicella-like exanthem as a specific COVID-19–associated skin manifestation: Multicenter case series of 22 patients." J Am Acad Dermatol 83 (2020): 280-285.

Google Scholar, Crossref, Indexed at

4. Recalcati, S., T. Barbagallo, L. A. Frasin and F. Prestinari, et al. "Acral cutaneous lesions in the time of COVID‐19." J Eur Acad Dermatol Venereol 34 (2020): e346.

Google Scholar, Crossref, Indexed at

5. Sachdeva, Muskaan, Raffaele Gianotti, Monica Shah and Lucia Bradanini, et al. "Cutaneous manifestations of COVID-19: Report of three cases and a review of literature." J Dermatol Sci 98 (2020): 75-81.

Google Scholar, Crossref, Indexed at

6. Rahimi, Hoda and Zohreh Tehranchinia. "A comprehensive review of cutaneous manifestations associated with COVID-19." Biomed Res Int 2020 (2020).

Google Scholar, Crossref, Indexed at